Evidence map›Paper›PMID 26105958›Full record

ArticleJournal of psychopharmacology (Oxford, England)2015

Negative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion.

Tamara Timić Stamenić, Srdjan Joksimović, Poonam Biawat, Tamara Stanković, Bojan Marković, James M Cook, Miroslav M Savić

Open access · greenAbstract read
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments.International journal of molecular sciences · 2021
    Review
  3. Basmisanil, a highly selective GABAScientific reports · 2021
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Tamara Timić StamenićDepartment of Pharmacology, University of Belgrade, Belgrade, Serbia.
Srdjan JoksimovićDepartment of Pharmacology, University of Belgrade, Belgrade, Serbia.
Poonam BiawatDepartment of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
Tamara StankovićDepartment of Pharmacology, University of Belgrade, Belgrade, Serbia.
Bojan MarkovićDepartment of Pharmaceutical Chemistry, University of Belgrade, Belgrade, Serbia.
James M CookDepartment of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
Miroslav M SavićDepartment of Pharmacology, University of Belgrade, Belgrade, Serbia miroslav@pharmacy.bg.ac.rs.
University of Belgrade · RSUniversity of Wisconsin–Milwaukee · US

Funding

SELECTIVE ANXIOLYTICS VIA BZR SUBTYPE SPECIFIC LIGANDSR01MH046851 · NIMH · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 1991 to 2010
$4.4M
Novel GABA-A Modulators as Cognitive EnhancersR01AG035361 · NIA · UNIVERSITY OF MISSISSIPPI MED CTR · PI ROWLETT, JAMES K · 2010 to 2014
$2.5M
Design of New Therapeutic Agents to Treat SchizophreniaR01MH096463 · NIMH · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2013 to 2017
$1.9M
Synthesis of Alpha2/Alpha3 GABA Agonists to Treat Neuropathic PainR01NS076517 · NINDS · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2012 to 2015
$1.3M
NIA NIH HHS AG035361NIA NIH HHS R01 AG035361NIMH NIH HHS MH096463NIMH NIH HHS R01 MH046851NIMH NIH HHS R01 MH096463NINDS NIH HHS R01 NS076517
6 · The paper itself

Abstract

Reportedly, negative modulation of α5 GABAA receptors may improve cognition in normal and pharmacologically-impaired animals, and such modulation has been proposed as an avenue for treatment of cognitive symptoms in schizophrenia. This study assessed the actions of PWZ-029, administered at doses (2, 5, and 10 mg/kg) at which it reached micromolar concentrations in brain tissue with estimated free concentrations adequate for selective modulation of α5 GABAA receptors, in three cognitive tasks in male Wistar rats acutely treated with the noncompetitive N-methyl-d-aspartate receptor antagonist, MK-801 (0.1 mg/kg), as well in tests of locomotor activity potentiated by MK-801 (0.2 mg/kg) or amphetamine (0.5 mg/kg). In a hormetic-like manner, only 5 mg/kg PWZ-029 reversed MK-801-induced deficits in novel object recognition test (visual recognition memory), whereas in the Morris water maze, the 2 mg/kg dose of PWZ-029 exerted partial beneficial effects on spatial learning impairment. PWZ-029 did not affect recognition memory deficits in social novelty discrimination procedure. Motor hyperactivity induced with MK-801 or amphetamine was not preventable by PWZ-029. Our results show that certain MK-801-induced memory deficits can be ameliorated by negative modulation of α5 GABAA receptors, and point to the need for further elucidation of their translational relevance to cognitive deterioration in schizophrenia.

Indexed as

AmphetamineAnimalsBehavior, AnimalBenzodiazepinesCognition DisordersDizocilpine MaleateHyperkinesisMaleMaze LearningMemory DisordersRatsRats, WistarReceptors, GABA-AReceptors, N-Methyl-D-AspartateSchizophreniaAmphetamineBenzodiazepinesDizocilpine MaleatePWZ-029Receptors, GABA-AReceptors, N-Methyl-D-Aspartateamphetaminedizocilpinefree brain concentrationMorris water mazenovel object recognition testPWZ-029social novelty discrimination procedure

Identifiers

PMID26105958
PMCPMC4861997
OpenAlexW2111567485

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.